Scarica l'app Stockscreener
45.10
2.15%
0.95
Dopo l'orario di chiusura:
45.08
-0.02
-0.04%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$44.15
Aprire:
$44.18
Volume 24 ore:
35.90M
Relative Volume:
2.77
Capitalizzazione di mercato:
$91.80B
Reddito:
$47.70B
Utile/perdita netta:
$5.07B
Rapporto P/E:
18.19
EPS:
2.48
Flusso di cassa netto:
$14.58B
1 W Prestazione:
+0.42%
1M Prestazione:
-4.41%
6M Prestazione:
-26.05%
1 anno Prestazione:
-12.83%
Intervallo 1D:
$44.12
$45.53
Intervallo di 1 settimana:
$43.19
$45.53
Portata 52W:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
45.10 | 89.86B | 47.70B | 5.07B | 14.58B | 2.48 |
|
LLY
Lilly Eli Co
|
763.00 | 651.28B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
185.42 | 437.40B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
231.54 | 394.23B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.24 | 240.24B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
83.93 | 196.28B | 63.43B | 16.42B | 14.72B | 6.49 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Judge denies motions by Bristol-Myers Squibb, State Street IM to dismiss PRT lawsuit - Pensions & Investments
Bristol Myers Squibb call volume above normal and directionally bullish - TipRanks
Multiple Modalities in the Oncology Market Size, Regional Growth and Trends - GlobeNewswire Inc.
Bristol-Myers Retirees’ Pension De-Risking Suit Moves Forward - Bloomberg Law News
Bristol Myers Squibb Company $BMY Position Cut by Capital Investment Advisors LLC - MarketBeat
JLL: Bristol Myers Squibb eyes sale, partial leaseback of 1.2 million sq. ft. Summit campus - Real Estate NJ
Bristol-Myers Squibb Company (BMY) Stock Analysis: 20% Upside Potential Amid Strong Dividend Yield - DirectorsTalk Interviews
Fort Washington Investment Advisors Inc. OH Acquires 7,095 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
KG&L Capital Management LLC Buys 39,136 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios - Insider Monkey
State of Alaska Department of Revenue Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Position Trimmed by TD Private Client Wealth LLC - MarketBeat
Trump's Drug Tariffs 'A Meaningful Commercial Hit' For Americans, Says AnalystEli Lilly (NYSE:LLY), Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Squibb discovers new TLR7 agonists - BioWorld MedTech
BMS adds discounted psoriasis drug to its DTC channel - pharmaphorum
Meyer Handelman Co. Has $24.44 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
BMS Expands Patient Options With Direct-to-Patient Platform - Dermatology Times
Bristol Myers Squibb to Offer More Than 80% off Sotyktu List Price - Managed Healthcare Executive
Bristol Myers Squibb leans into direct-to-consumer with telehealth launch, drug price drop - eMarketer
Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026 - Stocktwits
Bristol Myers to sell psoriasis drug at over 80% discount to some US patients - Reuters
BMS expands DTC offering with Sotyktu addition - Pharmaceutical Technology
PGIM Jennison Health Sciences Fund Sold its Position in Bristol-Myers Squibb Co. (BMY) in Q2 - Insider Monkey
Bristol Myers Squibb (BMY) Expands Discounted Drug Offerings - GuruFocus
Bristol Myers (BMY) Expands Direct Patient Access to Key Medicat - GuruFocus
Bristol Myers expands DTC offerings (BMY:NYSE) - Seeking Alpha
Bristol to Sell 80% Off Psoriasis Pill After Trump Demand - Bloomberg.com
Bristol Myers Squibb to offer steep discounts on Eliquis and Sotyktu - Investing.com Canada
Bristol Myers Squibb Builds on Eliquis (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu (deucravacitinib) - TradingView
80% Price Cut: Bristol Myers Squibb Makes Breakthrough Psoriasis Drug Sotyktu More Accessible - Stock Titan
Bristol Myers (BMY) Advances in Pulmonary Fibrosis Treatment - GuruFocus
Bristol to Sell Psoriasis Pill for 80% Off After Trump Demand - Bloomberg.com
FDA issues complete response letter for Bristol-Myers Squibb's hepatitis C drug daclatasvir - FirstWord Pharma
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Bristol-Myers Squibb's Opdivo superior to chemotherapy in Phase III trial in advanced melanoma - FirstWord Pharma
Bristol-Myers Squibb (BMY) Faces Extended Losses Amid Analyst Op - GuruFocus
Pharma Is Pushing $200,000 Cancer Drugs When Cheaper Doses May Work - Bloomberg.com
BMS Phase III success with iberdomide - The Pharma Letter
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study - Yahoo Finance
Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients - Sahm
BMS eyes filings for myeloma 'celmod' iberdomide - pharmaphorum
When It Pays to Buy Stocks of Companies Clouded in Controversy - Morningstar
Bristol Myers Squibb’s new multiple myeloma therapy shows promise By Investing.com - Investing.com Nigeria
CHICAGO TRUST Co NA Sells 10,191 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Become a business supplier - Bristol Myers Squibb
Bristol-Myers Squibb Is Facing a Patent Cliff, but a Solid Pipeline Supports a Wide Moat - Morningstar
Bristol Myers Squibb Company $BMY Shares Sold by UMB Bank n.a. - MarketBeat
Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment - Yahoo Finance
Bristol Myers’ US/UK List Price Parity Plan For Cobenfy Leverages Trump’s MFN Concerns - insights.citeline.com
BMS’s Iberdomide Scores First Major Phase III Win - insights.citeline.com
Diversified Trust Co Purchases 9,105 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.40%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):